Cargando…

The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment

Pediatric Adamantinomatous Craniopharyngiomas (ACPs) are histologically benign brain tumors that often follow an aggressive clinical course. Their suprasellar location leaves them in close proximity to critical neurological and vascular structures and often results in significant neuroendocrine morb...

Descripción completa

Detalles Bibliográficos
Autores principales: Whelan, Ros, Prince, Eric, Gilani, Ahmed, Hankinson, Todd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074265/
https://www.ncbi.nlm.nih.gov/pubmed/32075140
http://dx.doi.org/10.3390/jcm9020519
_version_ 1783506793848111104
author Whelan, Ros
Prince, Eric
Gilani, Ahmed
Hankinson, Todd
author_facet Whelan, Ros
Prince, Eric
Gilani, Ahmed
Hankinson, Todd
author_sort Whelan, Ros
collection PubMed
description Pediatric Adamantinomatous Craniopharyngiomas (ACPs) are histologically benign brain tumors that often follow an aggressive clinical course. Their suprasellar location leaves them in close proximity to critical neurological and vascular structures and often results in significant neuroendocrine morbidity. Current treatment paradigms, involving surgical resection and radiotherapy, confer significant morbidity to patients and there is an obvious need to discover effective and safe alternative treatments. Recent years have witnessed significant efforts to fully detail the genomic, transcriptomic and proteomic make-up of these tumors, in an attempt to identify potential therapeutic targets. These studies have resulted in ever mounting evidence that inflammatory processes and the immune response play a critical role in the pathogenesis of both the solid and cystic portion of ACPs. Several inflammatory and immune markers have been identified in both the cyst fluid and solid tumor tissue of ACP. Due to the existence of effective agents that target them, IL-6 and immune checkpoint inhibitors seem to present the most likely immediate candidates for clinical trials of targeted immune-related therapy in ACP. If effective, such agents may result in a paradigm shift in treatment that ultimately reduces morbidity and results in better outcomes for our patients.
format Online
Article
Text
id pubmed-7074265
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70742652020-03-19 The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment Whelan, Ros Prince, Eric Gilani, Ahmed Hankinson, Todd J Clin Med Review Pediatric Adamantinomatous Craniopharyngiomas (ACPs) are histologically benign brain tumors that often follow an aggressive clinical course. Their suprasellar location leaves them in close proximity to critical neurological and vascular structures and often results in significant neuroendocrine morbidity. Current treatment paradigms, involving surgical resection and radiotherapy, confer significant morbidity to patients and there is an obvious need to discover effective and safe alternative treatments. Recent years have witnessed significant efforts to fully detail the genomic, transcriptomic and proteomic make-up of these tumors, in an attempt to identify potential therapeutic targets. These studies have resulted in ever mounting evidence that inflammatory processes and the immune response play a critical role in the pathogenesis of both the solid and cystic portion of ACPs. Several inflammatory and immune markers have been identified in both the cyst fluid and solid tumor tissue of ACP. Due to the existence of effective agents that target them, IL-6 and immune checkpoint inhibitors seem to present the most likely immediate candidates for clinical trials of targeted immune-related therapy in ACP. If effective, such agents may result in a paradigm shift in treatment that ultimately reduces morbidity and results in better outcomes for our patients. MDPI 2020-02-14 /pmc/articles/PMC7074265/ /pubmed/32075140 http://dx.doi.org/10.3390/jcm9020519 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Whelan, Ros
Prince, Eric
Gilani, Ahmed
Hankinson, Todd
The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment
title The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment
title_full The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment
title_fullStr The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment
title_full_unstemmed The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment
title_short The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment
title_sort inflammatory milieu of adamantinomatous craniopharyngioma and its implications for treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074265/
https://www.ncbi.nlm.nih.gov/pubmed/32075140
http://dx.doi.org/10.3390/jcm9020519
work_keys_str_mv AT whelanros theinflammatorymilieuofadamantinomatouscraniopharyngiomaanditsimplicationsfortreatment
AT princeeric theinflammatorymilieuofadamantinomatouscraniopharyngiomaanditsimplicationsfortreatment
AT gilaniahmed theinflammatorymilieuofadamantinomatouscraniopharyngiomaanditsimplicationsfortreatment
AT hankinsontodd theinflammatorymilieuofadamantinomatouscraniopharyngiomaanditsimplicationsfortreatment
AT whelanros inflammatorymilieuofadamantinomatouscraniopharyngiomaanditsimplicationsfortreatment
AT princeeric inflammatorymilieuofadamantinomatouscraniopharyngiomaanditsimplicationsfortreatment
AT gilaniahmed inflammatorymilieuofadamantinomatouscraniopharyngiomaanditsimplicationsfortreatment
AT hankinsontodd inflammatorymilieuofadamantinomatouscraniopharyngiomaanditsimplicationsfortreatment